Central Serous Chorioretinopathy (CSCR): Causes, Treatment, and Where Integrative Care Fits

In short. Central serous chorioretinopathy (CSC, or CSCR) is a pocket of fluid under the retina that blurs and bends central vision. Most first episodes clear on their own within two to three months, and vision usually recovers well [1]. Steroid medicines, in any form, are the strongest known trigger you can change [2,3]. Tell your eye doctor about every steroid you use, but never stop a prescribed steroid without the doctor who prescribed it. If fluid lasts for months, half-dose photodynamic therapy has the best trial evidence [4,5]. Integrative care can sit alongside this plan; it does not treat CSC.

What CSC is. CSC mostly affects men between about 20 and 50. The choroid, a layer of blood vessels under the retina, becomes thick and leaky. Fluid seeps through the pigment layer of the retina and lifts the macula, like a small blister.

About 10 men per 100,000 develop CSC each year, around six times the rate in women [1]. In a US population study, 31% of people had at least one recurrence [6].

Typical symptoms are a blurred or dim patch in the centre of vision and straight lines that look bent. Objects can look smaller and colours washed out. It usually affects one eye at a time.

An OCT scan, a quick light-based picture of the retina, shows the fluid and the thick choroid. Fluorescein angiography shows where the fluid leaks, and indocyanine green (ICG) angiography shows the leaky choroid and guides laser treatment [7]. These tests also tell CSC apart from look-alikes such as wet macular degeneration and polypoidal choroidal vasculopathy [7].

• Acute CSC: a first episode, which often clears without treatment [1].
• Recurrent CSC: fluid that comes back after it has cleared [6].
• Chronic CSC: fluid that persists, usually for more than three to four months. Over time it can damage the light-sensing cells for good [8].

What raises the risk. One study compared 312 people with CSC and 312 without. Steroid tablets or injections carried an odds ratio of 37, and pregnancy an odds ratio of 7 [2].

In another study, 52% of people with acute CSC had used steroids, against 18% of matched controls [3]. They included tablets, drips, nasal sprays and joint injections [3]. Steroid eye drops [9], and skin creams and inhalers, even when used by someone you live with [10], have also been linked.

Cushing's syndrome, where the body makes too much cortisol, is another cause. In one series, 3 of 60 people with Cushing's syndrome had CSC [11]. Chronic CSC can even be its first sign [12].

A driven, "type A" personality [13], recent stress and shift work [14] have also been linked. Sildenafil (Viagra) appears in case reports. But in a study of 577 men with CSC, use of these drugs was no higher than in men without it [15].

The evidence on H. pylori, a stomach bacterium, is mixed. A review of eight studies found no clear link [16], and treating it did not reduce fluid in trials [17].

Treatments with good evidence

Watching, and reviewing triggers, in acute CSC. Because first episodes often clear on their own, observation is the usual first step [18]. Your eye doctor will repeat OCT scans to check that the fluid is going. Your prescriber may be able to lower the steroid dose or switch to another medicine, but that is their decision with you.

Half-dose photodynamic therapy (PDT), for chronic CSC. A light-sensitive drug, verteporfin, is given by drip into an arm vein, and a low-energy laser activates it over the leaky area. Verteporfin is licensed for other retinal conditions, so its use in CSC is off-label [19]. You must avoid direct sunlight and bright indoor light for five days afterwards [19].

The PLACE trial treated 179 people with chronic CSC. At six to eight weeks, fluid had cleared in 51.2% after half-dose PDT, against 13.8% after micropulse laser [4]. By seven to eight months, 67.2% and 28.8% were dry, and vision gains were larger with PDT (about 4.6 versus 1.4 letters) [4].

In the SPECTRA trial of 107 people, 78% were dry three months after half-dose PDT, against 17% on eplerenone tablets [5]. Side effects were reported in 6% and 33% [5]. Verteporfin supplies have at times been short [17].

What the Cochrane review says. The 2025 Cochrane review pooled 67 randomised trials with 4,015 people, most of them small and poorly reported [8]. It could not show that any treatment gave better eyesight than another, though low-dose PDT ranked highest [8]. In plain terms: half-dose PDT dries the retina more reliably than the alternatives, but the long-term vision benefit over waiting is less certain.

Treatments with some evidence

Thermal laser. Standard laser can seal a single leak that sits well away from the centre of the macula [7]. It is not used near the centre, because it leaves a small scar.

Micropulse laser. This laser does not scar the retina. In PLACE it cleared fluid far less often than half-dose PDT [4], so it is mainly used when PDT is not available or suitable.

Eplerenone and spironolactone. These tablets block a hormone receptor linked to CSC. In the VICI trial of 114 people, eplerenone did not improve vision after 12 months compared with a dummy tablet [20]. A 2026 review found these drugs reduced fluid in 6 of 8 trials, with no clear gain in vision [17].

Treating Cushing's syndrome. In four patients whose chronic CSC led to a Cushing's diagnosis, treating the hormone problem cleared the fluid [12].

What is not proven

• Acupuncture and herbal medicine. The only acupuncture study we found followed nine people with chronic CSC, and fluid cleared in four by three months [21]. With no comparison group, and with CSC often clearing on its own, it cannot show that acupuncture helped. We have not found good trials of Chinese or Ayurvedic herbs.
• Vitamins and supplements. Small trials have tested lutein and crocin (from saffron). The Cochrane review rated confidence in these results as low [8]. No vitamin has been shown to clear the fluid.
• H. pylori treatment for CSC itself. It did not reduce fluid in trials [17]. Treat H. pylori if you have stomach symptoms and a positive test, not as an eye treatment.
• Anti-VEGF injections for CSC itself. These are unproven in CSC [7], although they are used if abnormal new vessels grow under the retina.
• Anything that asks you to stop a prescribed steroid on your own. The same goes for advice to delay a specialist review when fluid has lasted for months.

Where Netra fits

Netra Eye Institute is an acupuncture and Oriental medicine practice. We do not diagnose or treat CSC, and we do not replace your retina specialist. Our role is adjunctive:

• We list every steroid you or your household use: inhalers, nasal sprays, skin creams, joint injections and eye drops. We pass this list to your eye doctor and prescriber. We never advise stopping a prescribed steroid.
• We offer acupuncture and, where appropriate, Chinese herbal medicine within Netra Restoration Therapy (NRT), with the evidence explained before you start. Herbs are reviewed against your medicines. We avoid unlabelled imported remedies, because some have been found to contain hidden steroids [22].
• We talk through sleep, shift patterns and stress, which have been linked to CSC. Changing them has not been proven to clear the fluid.
• We share what we see with your eye doctor. We refer back quickly if your vision changes, or if fluid is still present after about three months.

NRT is not a treatment for central serous chorioretinopathy and does not replace observation, photodynamic therapy or laser. For Ayurvedic approaches, see Ayurvedic treatment for central serous retinopathy. If you want to talk through whether integrative care makes sense alongside your treatment, request a consultation.

Questions people ask

What is CSCR?

It is fluid under the retina caused by a thick, leaky choroid underneath it. It blurs central vision, usually in one eye. CSCR, CSR and CSC are different short forms of the same condition.

What causes central serous retinopathy?

The exact cause is not known. Steroid medicines are the strongest known trigger. Others include pregnancy, Cushing's syndrome, stress and shift work [2,11,14]. Many people have no clear trigger.

Does caffeine make central serous retinopathy worse?

One study compared 83 people with CSC and 83 without, and found higher caffeine intake in the CSC group [23]. That shows a link, not a cause, and no trial has tested cutting caffeine. Cutting back is reasonable if you drink a lot, but it is not a treatment.

Are there vitamins for central serous retinopathy?

None has been shown to clear the fluid or protect vision. Small trials of lutein and saffron extract exist, but the evidence is weak [8]. Ask your doctor before starting any supplement.

Is there a natural treatment for central serous retinopathy?

The most natural course is that a first episode often settles on its own [1]. Removing triggers, with your prescriber's help, is the step most likely to matter. No herb, diet or supplement has been shown to clear chronic fluid.

Can acupuncture therapy help central serous retinopathy?

It has not been tested in a proper trial. A small study without a comparison group cannot separate acupuncture from natural recovery [21]. Acupuncture can be used alongside your specialist's care, not instead of it.

References

1. Liew G, Quin G, Gillies M, et al. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2013;41(2):201-214.
2. Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004;111(2):244-249.
3. Carvalho-Recchia CA, Yannuzzi LA, Negrão S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109(10):1834-1837.
4. van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology. 2018;125(10):1547-1555.
5. van Rijssen TJ, van Dijk EHC, Tsonaka R, et al. Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol. 2022;233:101-110.
6. Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008;115(1):169-173.
7. Quin G, Liew G, Ho IV, et al. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol. 2013;41(2):187-200.
8. Lange CA, Qureshi R, Pauleikhoff L. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2025;6:CD011841.
9. Chang YS, Weng SF, Chang C, et al. Associations between topical ophthalmic corticosteroids and central serous chorioretinopathy: a Taiwanese population-based study. Invest Ophthalmol Vis Sci. 2015;56(6):4083-4089.
10. Thinda S, Lam K, Park SS. Unintentional secondary exogenous corticosteroid exposure and central serous chorioretinopathy. Eye (Lond). 2015;29(4):577-579.
11. Bouzas EA, Scott MH, Mastorakos G, et al. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol. 1993;111(9):1229-1233.
12. van Dijk EH, Dijkman G, Biermasz NR, et al. Chronic central serous chorioretinopathy as a presenting symptom of Cushing syndrome. Eur J Ophthalmol. 2016;26(5):442-448.
13. Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986;84:799-845.
14. Bousquet E, Dhundass M, Lehmann M, et al. Shift work: a risk factor for central serous chorioretinopathy. Am J Ophthalmol. 2016;165:23-28.
15. French DD, Margo CE. Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina. 2010;30(2):271-274.
16. Wu DW, Jiang FP, Ge G, et al. Association between central serous chorioretinopathy and Helicobacter pylori infection: a systematic review and meta-analysis. Int J Ophthalmol. 2024;17(6):1120-1127.
17. Hamzah F, Azrina A, Supanji S, et al. Oral therapeutic interventions for central serous chorioretinopathy: a systematic review. Graefes Arch Clin Exp Ophthalmol. 2026;264(9):2589-2599.
18. van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770.
19. US Food and Drug Administration. Visudyne (verteporfin for injection) prescribing information. Revised 2023. accessdata.fda.gov label 021119s034.
20. Lotery A, Sivaprasad S, O'Connell A, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10220):294-303.
21. Liang Z, Tian C. Acupuncture for chronic central serous chorioretinopathy: a prospective case series. Acupunct Med. 2016;34(6):471-475.
22. Park HJ, Cho SH, Lee JH, et al. Screening for corticosteroid adulterants in Korean herbal medicines. J Forensic Sci. 2016;61(1):226-229.
23. Mansour AM, Koaik M, Lima LH, et al. Physiologic and psychologic risk factors in central serous chorioretinopathy. Ophthalmol Retina. 2017;1(6):497-507.